Jovitta Jacob

1.0k total citations
23 papers, 273 citations indexed

About

Jovitta Jacob is a scholar working on Public Health, Environmental and Occupational Health, Genetics and Hematology. According to data from OpenAlex, Jovitta Jacob has authored 23 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Public Health, Environmental and Occupational Health, 14 papers in Genetics and 12 papers in Hematology. Recurrent topics in Jovitta Jacob's work include Acute Lymphoblastic Leukemia research (23 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Jovitta Jacob is often cited by papers focused on Acute Lymphoblastic Leukemia research (23 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Chronic Myeloid Leukemia Treatments (11 papers). Jovitta Jacob collaborates with scholars based in United States. Jovitta Jacob's co-authors include Nitin Jain, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Tapan M. Kadia, Nicholas J. Short and Marina Konopleva and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jovitta Jacob

22 papers receiving 271 citations

Peers

Jovitta Jacob
Comparison fields: 5 of 31
  • Public Health, Environmental and Occupational Health 233
  • Oncology 180
  • Hematology 141
  • Pediatrics, Perinatology and Child Health 70
  • Pathology and Forensic Medicine 63
Replace Monika Brüggemann with:
Monika Brüggemann Germany
Maria Khouri United States
Catherine Tuglus United States
Thomas Lipp Germany
Nikola Hagedorn Germany
Christiane Chen‐Santel Germany
Salma A. Al‐Hadad Iraq
Nora Mühlegger Austria
Christine Mauz‐Koerholz Germany
Walid Macaron United States
Monika Brüggemann Germany View profile →
Citations per field, relative to Jovitta Jacob
Jovitta Jacob · 1×
Citations per year, relative to Jovitta Jacob
Jovitta Jacob · 1×

Countries citing papers authored by Jovitta Jacob

Since Specialization
Citations

This map shows the geographic impact of Jovitta Jacob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jovitta Jacob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jovitta Jacob more than expected).

Fields of papers citing papers by Jovitta Jacob

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jovitta Jacob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jovitta Jacob. The network helps show where Jovitta Jacob may publish in the future.

Co-authorship network of co-authors of Jovitta Jacob

This figure shows the co-authorship network connecting the top 25 collaborators of Jovitta Jacob. A scholar is included among the top collaborators of Jovitta Jacob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jovitta Jacob. Jovitta Jacob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
2024 ·Blood ·Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi Haddad, Tapan M. Kadia, Koji Sasaki, (unknown), Koichi Takahashi, Courtney D. DiNardo, Naval Daver, Guillermo Garcia‐Manero, Farhad Ravandi, Jovitta Jacob, Rebecca Garris, Hagop Kantarjian
3
2
Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
2024 ·Blood ·Jayastu Senapati, Elias Jabbour, Nitin Jain, Fadi Haddad, Guillermo Garcia-Manero, (unknown), Tapan M. Kadia, Farhad Ravandi, Koji Sasaki, Courtney D. DiNardo, Koichi Takahashi, Rebecca Garris, Jovitta Jacob, (unknown), Guillermo Montalban‐Bravo, Nicholas J. Short, H. Kantarjian
3
3
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
2023 ·The Lancet Haematology ·Elias Jabbour, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Koji Sasaki, Tapan M. Kadia, Joseph D. Khoury, Sa A. Wang, Fadi Haddad, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
49
4
P373: UPDATES FROM A PHASE II TRIAL OF MINI-HYPER-CVD-INOTUZUMAB WITH OR WITHOUT BLINATUMOMAB IN OLDER PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
2023 ·HemaSphere ·Fadi Haddad, Elias Jabbour, (unknown), Nicholas J. Short, Lewis Nasr, Walid Macaron, (unknown), Farhad Ravandi, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Jovitta Jacob, (unknown), Christopher Loiselle, Anna Milton, Juan J. Rivera, Rebecca Garris, Hagop Kantarjian
1
5
S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL
2023 ·HemaSphere ·Fadi Haddad, Elias Jabbour, (unknown), Nicholas J. Short, Walid Macaron, (unknown), Lewis Nasr, Nitin Jain, (unknown), Koji Sasaki, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Guillermo Garcia‐Manero, Tapan M. Kadia, Sa A. Wang, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Hagop M. Kantarjian
3
6
Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study.
2023 ·Journal of Clinical Oncology ·Lewis Nasr, Nicholas J. Short, Jayastu Senapati, (unknown), Nitin Jain, Marina Konopleva, Walid Macaron, Farhad Ravandi, Courtney D. DiNardo, Koji Sasaki, Alessandra Ferrajoli, (unknown), (unknown), Jovitta Jacob, (unknown), Anna Milton, Christopher Loiselle, Rebecca Garris, Hagop M. Kantarjian, Elias Jabbour
2
7
Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial.
2023 ·Journal of Clinical Oncology ·(unknown), Elias Jabbour, Fadi Haddad, Nicholas J. Short, Lewis Nasr, Walid Macaron, (unknown), Farhad Ravandi, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Jovitta Jacob, (unknown), Christopher Loiselle, Anna Milton, Juan J. Rivera, Rebecca Garris, Hagop M. Kantarjian
1
8
Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
2023 ·Blood ·(unknown), Elias Jabbour, Fadi Haddad, Nicholas J. Short, Nitin Jain, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Lewis Nasr, Courtney D. DiNardo, (unknown), Jovitta Jacob, (unknown), Christopher Loiselle, Anna Milton, Juan J. Rivera, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
3
9
A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
2022 ·Blood ·Jayastu Senapati, Nicholas J. Short, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masárová, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, (unknown), Anna Milton, Christopher Loiselle, Rebecca Garris, Hagop Kantarjian, Elias Jabbour
5
10
Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia
2022 ·SSRN Electronic Journal ·Hagop M. Kantarjian, Nitin Jain, Koji Sasaki, Elias Jabbour, Fadi Haddad, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Jeffrey L. Jorgensen, Issa F. Khouri, Partow Kebriaei, Yesid Alvarado, Tapan M. Kadia, Shilpa Paul, Guillermo Garcia‐Manero, Bouthaina S. Dabaja, Musa Yılmaz, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Farhad Ravandi
2
11
Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).
2022 ·Journal of Clinical Oncology ·Walid Macaron, Hagop M. Kantarjian, Nicholas J. Short, Farhad Ravandi, Nitin Jain, Tapan M. Kadia, Fadi Haddad, (unknown), Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, William G. Wierda, Jovitta Jacob, (unknown), Christopher Loiselle, Anna Milton, Juan J. Rivera, Rebecca Garris, Elias Jabbour
5
12
A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
2021 ·Blood ·Nicholas J. Short, Hagop M. Kantarjian, Yesid Alvarado, Jan A. Burger, Nitin Jain, Marina Konopleva, Farhad Ravandi, Courtney D. DiNardo, Lucia Masárová, Koji Sasaki, Philip A. Thompson, Alessandra Ferrajoli, Jovitta Jacob, Anna Milton, Rebecca Garris, Elias Jabbour
2
13
Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis
2019 ·Cancer ·Elias Jabbour, Koji Sasaki, Farhad Ravandi, Nicholas J. Short, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Marina Konopleva, Nitin Jain, Jörge E. Cortes, Ghayas C. Issa, Jovitta Jacob, Monica Kwari, Philip A. Thompson, Rebecca Garris, Naveen Pemmaraju, Musa Yılmaz, Susan O’Brien, Hagop M. Kantarjian
66
14
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
2018 ·Cancer ·Elias Jabbour, Koji Sasaki, Farhad Ravandi, Xuelin Huang, Nicholas J. Short, Maria Khouri, Partow Kebriaei, Jan A. Burger, Joseph D. Khoury, Jeffrey L. Jorgensen, Nitin Jain, Marina Konopleva, Guillermo Garcia‐Manero, Tapan M. Kadia, Jörge E. Cortes, Jovitta Jacob, Kathryn Montalbano, Rebecca Garris, Susan O’Brien, Hagop M. Kantarjian
76
15
Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis
2018 ·Blood ·Koji Sasaki, Hagop M. Kantarjian, Nicholas J. Short, Farhad Ravandi, Maria Khouri, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Marina Konopleva, Nitin Jain, Ghayas C. Issa, Jovitta Jacob, Rebecca Garris, Musa Yılmaz, Philip A. Thompson, (unknown), Naveen Pemmaraju, Jörge E. Cortes, Susan O’Brien, Elias Jabbour
2
16
Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).
2017 ·Journal of Clinical Oncology ·Rita Assi, Hagop M. Kantarjian, Farhad Ravandi, Susan O’Brien, Partow Kebriaei, Deborah A. Thomas, Guillermo Garcia‐Manero, Issa F. Khouri, Richard E. Champlin, Tapan M. Kadia, Jörge E. Cortes, Nitin Jain, Marina Konopleva, (unknown), Zeev Estrov, Koichi Takahashi, Koji Sasaki, Jovitta Jacob, Rebecca Garris, Elias Jabbour
1
17
Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial
2016 ·Blood ·Koji Sasaki, Elias Jabbour, Susan O’Brien, Farhad Ravandi, Deborah A. Thomas, Guillermo Garcia‐Manero, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Nicholas J. Short, Naveen Pemmaraju, Yesid Alvarado, Jovitta Jacob, Rebecca Garris, Philip A. Thompson, Jörge E. Cortes, Hagop M. Kantarjian
17
18
Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin
2015 ·Blood ·Jad Chahoud, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Koji Sasaki, Tapan M. Kadia, Jörge E. Cortes, Maria Khouri, Farhad Ravandi, (unknown), Alessandra Ferrajoli, Jovitta Jacob, Naveen Pemmaraju, Naval Daver, Rebecca Garris, Elias Jabbour
2
19
Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)
2015 ·Blood ·Elias Jabbour, Susan O’Brien, Koji Sasaki, Deborah A. Thomas, Guillermo Garcia‐Manero, Farhad Ravandi, Gautam Borthakur, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jörge E. Cortes, Hagop M. Kantarjian
15
20
Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
2015 ·Blood ·Koji Sasaki, Hagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas, Farhad Ravandi, Guillermo Garcia‐Manero, Tapan M. Kadia, Nitin Jain, Marina Konopleva, Zeev Estrov, Koichi Takahashi, Maria Khouri, Jovitta Jacob, Rebecca Garris, Jörge E. Cortes, Elias Jabbour
11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monika Brüggemann Breakdown of academic impact, for papers by Maria Khouri Breakdown of academic impact, for papers by Catherine Tuglus Breakdown of academic impact, for papers by Thomas Lipp Breakdown of academic impact, for papers by Nikola Hagedorn Breakdown of academic impact, for papers by Christiane Chen‐Santel Breakdown of academic impact, for papers by Salma A. Al‐Hadad Breakdown of academic impact, for papers by Nora Mühlegger Breakdown of academic impact, for papers by Christine Mauz‐Koerholz Breakdown of academic impact, for papers by Walid Macaron
Rankless by CCL
2026